Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
8 papers
Recent·Most cited
S. Klute, R. Nchioua, A. Cordsmeier, J. Vishwakarma, L. Koepke, H. Alshammary, C. Jung, M. Hirschenberger, H. Hoenigsperger, J.-R. Fischer, F. Zech, S. Stenger, R. Serra-Moreno, A. S. Gonzalez-Reiche, E. M. Sordillo, , K. M. Sparrer
The paper shows that the T9I mutation in the SARS-CoV-2 E protein confers autophagy resistance in Omicron variants, contributing to their spread.
bioRxiv · Apr 23, 2024 · PreprintMicrobiology
M. Hayn, M. Hirschenberger, L. Koepke, J. H. Straub, R. Nchioua, M. H. Christensen, S. Klute, C. Prelli Bozzo, W. Aftab, F. Zech, C. Conzelmann, J. A. Mueller, S. Srinivasachar Badarinarayan, C. M. Stuerzel, I. Forne, , K. M. J. Sparrer
This study identifies SARS-CoV-2's vulnerability to IFN-γ and -λ due to its inefficient antagonism of type I and II IFN responses, suggesting potential therapeutic strategies.
bioRxiv · Oct 15, 2020Microbiology
C. Conzelmann, A. Gilg, R. Gross, D. Schuetz, N. Preising, L. Staendker, B. Jahrsdoerfer, H. Schrezenmeier, K. M. Sparrer, T. Stamminger, S. Stenger, J. Muench, J. A. Mueller
This paper introduces an enzyme-based immunodetection assay to quantify SARS-CoV-2 infection by measuring viral spike protein expression in cell cultures.
Antiviral Research · Sep 1, 2020Peer-reviewedMicrobiology
C. Prelli Bozzo, R. Nchioua, M. Volcic, J. Krueger, S. Heller, C. M. Stuerzel, D. Kmiec, C. Conzelmann, J. A. Mueller, F. Zech, D. Schuetz, L. Koepke, E. Braun, R. Gross, L. Wettstein, , F. Kirchhoff
This study shows that IFITM proteins are required for SARS-CoV-2 infection and can be targeted to inhibit viral entry and replication.
bioRxiv · Aug 18, 2020 · PreprintMicrobiology
L. Wettstein, C. Conzelmann, J. A. Mueller, T. Weil, R. Gross, M. Hirschenberger, A. Seidel, S. Klute, c. Prelli-Bozzo, F. Zech, N. Preising, G. Fois, R. Lochbaum, P. Knaff, V. Mailaender, , J. Muench
The paper identifies 1-antitrypsin as a specific inhibitor of SARS-CoV-2, showing it blocks viral infection of human airway epithelium at physiological concentrations.
bioRxiv · Jul 2, 2020 · PreprintMicrobiology
C. Conzelmann, R. Gross, T. L. Meister, D. Todt, A. Krawczyk, U. Dittmer, S. Stenger, J. Muench, E. Steinmann, J. A. Mueller, S. Pfaender
This study shows that Holder pasteurization inactivates SARS-CoV-2 in human breast milk, offering a safe method for infected mothers to breastfeed.
bioRxiv · Jun 17, 2020 · PreprintMicrobiology
J. Krueger, R. Gross, C. Conzelmann, J. A. Mueller, L. Koepke, K. Sparrer, D. Schuetz, T. Seufferlein, T. F. E. Barth, S. Stenger, S. Heller, A. Kleger, J. Muench
This study uses human intestinal organoids to show that remdesivir inhibits SARS-CoV-2 replication, while famotidine does not.
bioRxiv · Jun 10, 2020 · PreprintMicrobiology
R. Nchioua, D. Kmiec, J. Mueller, C. Conzelmann, R. Gross, C. M. Swanson, S. Neil, S. Stenger, D. Sauter, J. Muench, K. M. Sparrer, F. Kirchhoff
This paper identifies ZAP as an IFN-induced antiviral effector that restricts SARS-CoV-2 by targeting CpG dinucleotides, though SARS-CoV-2 may be adapted to low CpG environments.
bioRxiv · Jun 4, 2020Microbiology